LifeMD (NASDAQ:LFMD) Sets New 52-Week High at $12.50

LifeMD, Inc. (NASDAQ:LFMD)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $12.50 and last traded at $12.49, with a volume of 602630 shares trading hands. The stock had previously closed at $11.64.

Analysts Set New Price Targets

A number of equities research analysts have commented on LFMD shares. BTIG Research raised their target price on shares of LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. HC Wainwright lifted their target price on shares of LifeMD from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, January 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, LifeMD currently has a consensus rating of “Buy” and a consensus target price of $10.40.

LifeMD Stock Up 7.3 %

The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22. The company has a 50 day simple moving average of $9.70 and a two-hundred day simple moving average of $7.87. The firm has a market capitalization of $510.72 million, a P/E ratio of -17.84 and a beta of 1.38.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Monday, March 11th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The company had revenue of $44.86 million for the quarter, compared to the consensus estimate of $40.65 million. On average, equities analysts predict that LifeMD, Inc. will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LFMD. Dorsey Wright & Associates bought a new position in LifeMD during the third quarter valued at approximately $37,000. Tower Research Capital LLC TRC boosted its position in shares of LifeMD by 266.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $38,000 after acquiring an additional 3,348 shares during the last quarter. Worth Venture Partners LLC purchased a new position in shares of LifeMD in the third quarter valued at $64,000. Freedom Wealth Alliance LLC bought a new stake in LifeMD in the third quarter worth $68,000. Finally, Thompson Davis & CO. Inc. purchased a new stake in LifeMD during the fourth quarter valued at $117,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.